Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer.
about
MET Inhibition Results in DNA Breaks and Synergistically Sensitizes Tumor Cells to DNA-Damaging Agents Potentially by Breaching a Damage-Induced Checkpoint ArrestEfficacy of sorafenib monotherapy versus sorafenib-based loco-regional treatments in advanced hepatocellular carcinoma.Use of protein array technology to investigate receptor tyrosine kinases activated in hepatocellular carcinomaDesign and Evaluation of Novel Antimicrobial and Anticancer Agents Among Tetrazolo[1,5-c]quinazoline-5-thione S-Derivatives.Antiangiogenic effects of noscapine enhance radioresponse for GL261 tumors.Targeted therapy of spontaneous murine pancreatic tumors by polymeric micelles prolongs survival and prevents peritoneal metastasis.Antiangiogenics and radiotherapy.The role of apoptosis in radiation oncology.Current status of cediranib: the rapid development of a novel anti-angiogenic therapy.Emerging molecular targeted therapies in the treatment of head and neck cancer.Modulating the tumor microenvironment to increase radiation responsiveness.Targeting Enox1 in tumor stroma increases the efficacy of fractionated radiotherapy.In pursuit of new anti-angiogenic therapies for cancer treatmentBlocking the interaction of vascular endothelial growth factor receptors with their ligands and their effector signaling as a novel therapeutic target for cancer: time for a new look?Microenvironment and radiation therapyReceptor tyrosine kinase inhibitors: Are they real tumor killers?Alterations in daily sequencing of axitinib and fractionated radiotherapy do not affect tumor growth inhibition or pathophysiological response.Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts.Evaluation of human brain tumor heterogeneity using multiple T1-based MRI signal weighting approaches.Radiotherapy in combination with vascular-targeted therapies.Inhibition of vascular endothelial growth factor signalling using cediranib (RECENTIN; AZD2171) enhances radiation response and causes substantial physiological changes in lung tumour xenografts.Challenges and opportunities of using stereotactic body radiotherapy with anti-angiogenesis agents in tumor therapy.Cediranib enhances control of wild type EGFR and EGFRvIII-expressing gliomas through potentiating temozolomide, but not through radiosensitization: implications for the clinic.
P2860
Q34972637-1D8A80F1-285B-4F79-8FBF-0FA0858166ECQ35025403-AD0AC9EF-1BAA-4E7D-856D-ABCD54EBF5EBQ36230812-391EF925-5BCF-4CA7-B81B-4DA0C7792CD0Q36743434-3B511A0C-6152-47DD-BF84-9065E50FEF39Q36947173-4E5F996F-CB78-475F-B3D0-4C38AEF7C6A7Q37010760-2687C249-5A3E-44D3-93B9-ED68FC30994CQ37222791-06BA15FF-2C7E-4C5F-AF78-1A509672756CQ37413111-1CC11867-72D5-4535-8720-C93E043D8100Q37486753-B4CF428E-1ED6-49D4-A1F9-BC7FDE77A062Q37515438-C115F680-7D38-401A-981D-DC08F6A11A84Q37613364-9CFDBA25-11A8-443A-B87E-59C4DB363A88Q37718465-AF57A957-2B1A-4955-9483-02903E02FC5FQ37825180-D07BAFE1-66B0-4F1B-96FB-D9A063E027B6Q37921797-37CBDE59-5F3D-4D49-8FA8-FDA69C8F9AC2Q38091084-59FC5ED2-55C7-4C26-B032-82D429031EB3Q38365290-613C32E7-8BA9-494F-80F4-73C7D76A539AQ39828661-8A6787CC-657E-410A-BB83-84904E703556Q40115231-D07E6CEE-D332-4B5C-8664-9064F4DB2EEBQ40212394-117875C0-F79C-4295-AA81-6A98A27B32F7Q42203737-B773A87C-5394-4562-BDF0-9EC62D98780DQ46344533-3DC32AE6-E79A-4BA2-866E-D4CCF90E774DQ53701730-B4E9C44B-9F34-49F9-92EA-03A8CFC36774Q54594692-CA3D62A0-EEDB-4C12-A949-8D2C3A4B09C4
P2860
Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Vascular endothelial growth fa ...... n mouse models of lung cancer.
@en
type
label
Vascular endothelial growth fa ...... n mouse models of lung cancer.
@en
prefLabel
Vascular endothelial growth fa ...... n mouse models of lung cancer.
@en
P2093
P1433
P1476
Vascular endothelial growth fa ...... n mouse models of lung cancer.
@en
P2093
Alan Sandler
Carolyn Cao
David H Johnson
Jeffrey M Albert
Percy S Ivy
P304
11409-11415
P356
10.1158/0008-5472.CAN-06-2414
P407
P577
2006-12-01T00:00:00Z